ALS nursing reference: assessment, interventions, and NCLEX tips

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that destroys both upper and lower motor neurons, leading to muscle weakness, paralysis, and eventually respiratory failure. It affects roughly 2 per 100,000 people per year, with a median survival of 2–5 years from symptom onset. Approximately 10% of cases are familial, most commonly linked to SOD1 and C9orf72 mutations; the remaining 90% are sporadic with no identified genetic cause. ALS is high-yield NCLEX content because it tests your ability to differentiate upper from lower motor neuron signs, prioritize respiratory assessment, and recognize the correct timing for interventions such as noninvasive ventilation and percutaneous endoscopic gastrostomy. This reference covers everything you need: pathophysiology, clinical presentation, staging, nursing assessment, pharmacology, and NCLEX-ready tips.

ALS quick-reference summary

Pathophysiology

ALS results from the progressive degeneration of two sets of motor neurons: upper motor neurons (UMNs) in the motor cortex and corticospinal tracts, and lower motor neurons (LMNs) in the anterior horn of the spinal cord and brainstem motor nuclei. The disease typically spreads contiguously across anatomical regions — from cortex to brainstem to spinal cord — though the precise mechanism of propagation is still under investigation.

Glutamate excitotoxicity is a central driver of UMN death. Excess extracellular glutamate overactivates NMDA and AMPA receptors, flooding neurons with calcium and triggering apoptotic cascades. Riluzole, the first FDA-approved ALS medication, works by blocking voltage-gated sodium channels and reducing presynaptic glutamate release, thereby limiting this excitotoxic injury.

Oxidative stress and mitochondrial dysfunction contribute to LMN death. Reactive oxygen species accumulate, overwhelming cellular antioxidant defenses. Edaravone, approved in 2017, acts as a free-radical scavenger and is thought to reduce oxidative stress-related neuronal damage — though its clinical effect is modest and primarily seen in early-stage patients.

SOD1 mutations (superoxide dismutase 1) were the first familial ALS gene identified and account for ~20% of familial cases. SOD1 normally converts superoxide radicals into hydrogen peroxide; loss-of-function or gain-of-toxic-function mutations impair this process. C9orf72 repeat expansions are the most common familial and sporadic ALS-associated mutation, accounting for ~40% of familial and ~7% of sporadic cases.

Cognitive and behavioral changes occur in up to 50% of patients to some degree. Approximately 15% meet criteria for ALS-frontotemporal dementia (ALS-FTD), characterized by executive dysfunction, disinhibition, and apathy. Preserved cognition cannot be assumed — always screen.

Clinical presentation — UMN vs LMN signs

The hallmark of ALS is the simultaneous presence of both UMN and LMN signs in the same patient. This distinguishes ALS from conditions that cause only one or the other.

This combination — spastic, hyperreflexic limbs with visible fasciculations and wasting — is the classic NCLEX presentation.

Onset patterns

Limb-onset (70%): The most common presentation. Weakness typically begins asymmetrically in a hand (fine motor difficulty — dropping keys, difficulty buttoning) or a foot (foot drop, tripping). The asymmetry at onset is characteristic. Spread follows spinal cord anatomy — cervical region → thoracic → lumbar, or the reverse.

Bulbar-onset (25%): Weakness begins in the muscles of speech and swallowing. Patients present with dysarthria (slurred or nasal speech), dysphagia (particularly for thin liquids), and sialorrhea (drooling due to impaired swallowing, not increased saliva production). Bulbar-onset carries a worse prognosis because respiratory muscle involvement occurs earlier. This group is at the highest aspiration risk and requires immediate SLP referral.

Respiratory-onset (rare, <5%): Diaphragm and accessory muscles are affected first, presenting with dyspnea on exertion or orthopnea before obvious limb weakness. Often misdiagnosed initially.

Bulbar symptoms in detail

• Dysarthria: Begins as mild slurring, progresses to dysphonia and anarthria. UMN-predominant bulbar involvement produces spastic dysarthria with hypernasality; LMN-predominant bulbar involvement produces flaccid dysarthria with tongue weakness and atrophy. Most ALS patients show features of both. Voice banking (recording phrases while speech is clear) should be initiated as early as possible.
• Dysphagia: Initially for thin liquids; progresses to solids. Screen with the bedside swallow test. Modified barium swallow study for formal assessment.
• Sialorrhea: Caused by reduced swallowing frequency, not hypersalivation. Treated with anticholinergics (glycopyrrolate, amitriptyline) or botulinum toxin injections to parotid/submandibular glands.

Diagnostic criteria

ALS diagnosis is clinical, supported by electrophysiology. There is no single confirmatory biomarker.

El Escorial / Awaji criteria classify certainty based on the number of spinal cord regions showing both UMN and LMN degeneration:

• Definite ALS: UMN + LMN signs in 3 regions (bulbar + 2 spinal, or 3 spinal)
• Probable ALS: UMN + LMN signs in 2 regions, with UMN signs rostral to LMN signs
• Probable laboratory-supported: UMN signs in ≥1 region + EMG evidence of LMN degeneration in ≥2 limbs
• Possible ALS: UMN + LMN signs in 1 region, or UMN signs alone in ≥2 regions

The Awaji criteria (2008 revision) give EMG evidence equivalent weight to clinical LMN signs, allowing earlier diagnosis.

EMG findings in ALS:

• Fibrillation potentials (spontaneous LMN discharge)
• Positive sharp waves
• Fasciculation potentials
• Large, polyphasic motor unit action potentials (chronic denervation/reinnervation)

What ALS is NOT — key differentiators for NCLEX:

ALS does not cause sensory loss. If a patient has numbness, tingling, or loss of proprioception, reconsider the diagnosis. This differentiates ALS from multiple sclerosis (which causes sensory demyelination) and spinal cord injury (which causes sensory level).

ALS does not cause bowel or bladder dysfunction until very late in disease. Early incontinence suggests another etiology (MS, SCI, cauda equina syndrome).

ALS does not cause extraocular muscle involvement until terminal stages. Eye movements are preserved — this is why eye-tracking communication devices remain viable even when all other movement is lost.

Staging and progression

ALSFRS-R (ALS Functional Rating Scale — Revised)

The ALSFRS-R is the primary tool for tracking ALS progression. It assesses 12 functional domains, each scored 0–4 (4 = normal, 0 = unable to perform). Maximum score: 48.

Average rate of ALSFRS-R decline is approximately 1 point per month, but varies significantly. Faster decline (>1.5 points/month) predicts shorter survival. An ALSFRS-R ≤25 combined with FVC <30% or refusal of mechanical ventilation is a common hospice eligibility threshold.

Disease staging systems

King’s College staging (1–4): Based on number of anatomical regions with clinical involvement (bulbar, cervical, thoracic, lumbosacral). Stage 1 = 1 region involved; Stage 4 = nutritional or respiratory failure requiring intervention.

MiToS (Milano-Torino Staging): A functional staging system based on loss of specific motor functions (walking, swallowing, communicating, breathing). Six stages (0–5); each stage reflects the loss of one additional function. MiToS 4–5 correlates with median survival under 12 months.

Nursing assessment

Respiratory assessment

Respiratory function is the most critical parameter to monitor in ALS. Respiratory failure is the leading cause of death, and proactive management improves both quality and length of life.

• Forced vital capacity (FVC%): The primary metric. Measured in pulmonary function laboratory or with hand-held spirometer. FVC below 50% predicted is the threshold for initiating noninvasive ventilation (NIV/BiPAP). Trend matters as much as absolute value — a rapid decline (>10%/6 months) warrants earlier intervention discussion.
• Sniff nasal inspiratory pressure (SNIP): A sensitive early indicator of diaphragm weakness, often more sensitive than FVC in bulbar-onset patients.
• Maximal inspiratory pressure (MIP): MIP more negative than −60 cmH₂O suggests significant inspiratory muscle weakness.
• Orthopnea: Inability to lie flat due to dyspnea is an early sign of diaphragm weakness and often precedes significant FVC decline. Ask about pillow use and nighttime awakenings with dyspnea. Orthopnea alone is sufficient indication for NIV initiation.
• SpO₂ and end-tidal CO₂: Hypoxemia and hypercapnia are late signs — do not wait for these before acting.

For neurological assessment frameworks, systematic respiratory monitoring should be integrated into every visit.

Swallowing and nutrition assessment

• Bedside swallow screen: 3-ounce water swallow test. Coughing, wet voice quality, or prolonged swallowing time during the test indicates dysphagia — refer to SLP for formal evaluation.
• ALSFRS-R swallowing domain: Track at every visit. Score of 2 or below (soft foods only or gastrostomy tube dependent) triggers PEG discussion.
• Weight tracking: Weigh at every visit. A 10% unintentional weight loss from baseline is a threshold indicator for PEG discussion. Malnutrition is an independent predictor of shorter survival.
• Caloric intake: ALS patients have elevated resting energy expenditure. Maintaining weight often requires caloric supplementation beyond typical recommendations.

Communication assessment

• Track speech intelligibility at each visit. When intelligibility drops to 80% with familiar listeners, refer immediately for augmentative and alternative communication (AAC) evaluation.
• Voice banking: When speech is still relatively clear, encourage patients to record a voice bank (ModelTalker, VocaliD) for use in speech-generating devices later. Referral should happen at diagnosis, not at communication breakdown.
• Assess upper extremity function — eye-gaze-based AAC devices become necessary when hand function is lost.

Functional and mobility assessment

• Falls risk: Upper and lower extremity weakness combined with spasticity makes falls a significant hazard. Refer early to physical therapy.
• Assess fine motor function (button manipulation, handwriting, utensil use) to guide OT interventions and timing of adaptive equipment.
• Track wheelchair readiness: Transition planning should begin before walking becomes unsafe, not after a fall.

Pain assessment

Pain is underrecognized and undertreated in ALS. Common sources include joint pain from immobility, muscle cramps (often nocturnal), shoulder pain from subluxation, and pressure injury from prolonged sitting. Use a validated pain scale at every visit.

Psychological assessment

• Screen for depression and anxiety at diagnosis and at regular intervals — both are common and treatable.
• Distinguish pseudobulbar affect (involuntary laughing or crying disproportionate to mood) from clinical depression. These have different presentations and different treatments.
• Assess caregiver burden. ALS places enormous demands on family caregivers; burnout leads to crisis hospitalizations and early institutionalization.

Nursing interventions

Respiratory management

The most important intervention in ALS nursing is proactive respiratory support. Do not wait for hypoxia.

Noninvasive ventilation (NIV/BiPAP):

• Initiate discussion when FVC approaches 50%, when orthopnea is present, or when MIP exceeds −60 cmH₂O.
• NIV (typically BiPAP in spontaneous-timed mode) extends survival by a median of 7–13 months and improves quality of life.
• Patient education: mask fitting, titration process, what to expect the first nights, cleaning and maintenance.
• Bulbar-onset patients may have more difficulty tolerating NIV due to mask seal issues with facial weakness — use hybrid or full-face masks.

Secretion management:

• Mechanical insufflation-exsufflation (MI-E, CoughAssist) devices augment cough when peak cough flow drops below 270 L/min.
• Mucolytics (guaifenesin) and saline nebulization can thin secretions.
• Manually assisted cough: caregiver-applied abdominal thrust timed to expiration.

Tracheostomy and invasive mechanical ventilation:

• Most patients decline tracheostomy. The decision is deeply personal and should be part of advance care planning conversations beginning at diagnosis.
• Patients who choose tracheostomy remain ventilator-dependent indefinitely. Frame as a commitment, not a temporary rescue.
• Nursing role: facilitate informed decision-making, ensure patient’s values and goals are documented, not persuade toward any particular choice.

Nutrition and swallowing management

• Implement modified diet textures and thickened liquids based on SLP recommendations.
• PEG placement: recommend when FVC is still above 50% — procedural risk is significantly higher when FVC is below 50% because sedation may precipitate respiratory failure.
• Enteral feeding management: teach the patient and caregiver tube care, feeding schedule, and how to recognize complications (tube displacement, aspiration, site infection, diarrhea).
• Appetite stimulants and caloric supplementation (high-calorie drinks, tube feeding formulas with high fat content) can slow weight loss. High-fat enteral formulas are often preferred because fat metabolism produces less CO₂ than carbohydrate metabolism, which reduces ventilatory load when respiratory reserve is already limited.

Communication support

• Refer to speech-language pathology at diagnosis for AAC evaluation, voice banking, and dysphagia management — not when speech fails.
• Low-tech options: alphabet boards, word prediction cards, ETRAN frames (eye-pointing).
• High-tech options: speech-generating devices (Tobii Dynavox, Accent), eye-gaze systems, brain-computer interfaces in late stage.
• Coordinate with insurance early — AAC device authorization takes months.

Mobility and safety

• Collaborate with physical therapy: ROM exercises to prevent contractures, gait aids (AFOs for foot drop, rollator walkers), wheelchair assessment.
• Falls prevention: home safety evaluation, grab bars, non-slip surfaces, hospital bed and raised toilet seat.
• Occupational therapy: adaptive utensils, dressing aids, environmental modifications to preserve independence.
• Pressure injury prevention: appropriate seating cushion, repositioning schedule, skin inspection.

Symptom management

Spasticity: Baclofen (first-line, oral or intrathecal for severe cases), tizanidine. PT with stretching program.

Muscle cramps: Levetiracetam has some evidence; mexiletine (sodium channel blocker) has been studied in ALS-specific trials. Magnesium and physical measures (stretching, heat) are often first tried. Quinine is no longer recommended due to cardiac risk.

Sialorrhea: Glycopyrrolate (anticholinergic, first-line), amitriptyline (useful when depression also present), botulinum toxin injections to parotid/submandibular glands (longer duration), hyoscine patch.

Pseudobulbar affect: Dextromethorphan/quinidine (Nuedexta) — FDA-approved specifically for pseudobulbar affect. Distinguish this from depression: pseudobulbar affect is involuntary, not sustained, and not related to underlying mood state.

Pain: Regular analgesic ladder — start with NSAIDs/acetaminophen, escalate to opioids as needed. In late disease, opioids are appropriate and recommended for dyspnea as well as pain. Nurses should advocate for adequate analgesia.

Constipation: Immobility, reduced fluid intake, and anticholinergic medications all contribute. Stool softeners (docusate), osmotic laxatives (polyethylene glycol), and adequate hydration.

Depression and anxiety: SSRIs and SNRIs. Mirtazapine has the added benefit of stimulating appetite. Benzodiazepines for anxiety and dyspnea in late stage.

Psychosocial care

• Refer to the ALS Association for multidisciplinary ALS clinic resources, equipment loan programs, and local support groups.
• Social work referral at diagnosis: financial assistance programs (Social Security Disability, Medicare, drug assistance programs), home health aide coordination, respite care.
• Caregiver education and support: hands-on training for transfers, suctioning, feeding tube care, BiPAP management.
• Palliative care introduction: frame palliative care as quality-of-life support alongside curative intent — not as “giving up.” Early palliative involvement improves outcomes.

Multidisciplinary ALS clinic model

ALS management follows a specialized multidisciplinary clinic model. A typical team includes neurologist, pulmonologist, gastroenterologist (for PEG placement), speech-language pathologist, physical therapist, occupational therapist, respiratory therapist, social worker, and palliative care. The nurse is the central coordinator – communicating across disciplines, ensuring interventions are sequenced correctly, and maintaining continuity between visits. Compare this coordinated care model with myasthenia gravis nursing, where multidisciplinary involvement is also critical but disease course and interventions differ substantially.

For a comparison of neurodegenerative disease nursing priorities, see the Parkinson’s disease nursing reference and multiple sclerosis nursing reference.

Pharmacology

For broader pharmacology context, the drug classifications nursing reference covers the major drug classes that appear on NCLEX.

Complications

Respiratory failure: The leading cause of death. Often progresses from nocturnal hypoventilation to daytime hypercapnia. Proactive NIV initiation and advance care planning are the primary nursing responses.

Aspiration pneumonia: Dysphagia and reduced cough strength create a direct aspiration pathway. Bulbar-onset patients are at highest risk. Upright positioning during and after meals, aspiration precautions, and SLP-guided diet modification are preventive measures. See the stroke nursing reference for aspiration precaution protocols applicable across neurological conditions.

Malnutrition and cachexia: Weight loss accelerates functional decline and shortens survival. PEG placement before FVC drops below 50% is the evidence-based standard.

Deep vein thrombosis: Immobility increases DVT risk. Compression stockings, hydration, and early mobility (while possible) are standard preventive interventions. Pharmacological prophylaxis may be considered in hospitalized patients.

Depression and suicidality: Major depression affects 10–25% of ALS patients. Screen regularly with validated tools (PHQ-9). Suicidality must be assessed directly — the loss of autonomy and anticipated suffering place patients at elevated risk. Hospice and palliative teams are important partners.

Caregiver burnout: ALS caregiving is among the most intensive in medicine. Burnout leads to inadequate patient care, caregiver health crises, and emergency institutionalization. Routine assessment of caregiver wellbeing is part of ALS nursing care.

Communication breakdown: Sudden inability to communicate is a quality-of-life crisis. AAC devices that are not arranged before speech loss cannot be rapidly deployed. Early referral prevents this emergency.

End-of-life considerations

Advance care planning

Advance care planning should begin at diagnosis, be revisited at key disease milestones, and be led by the clinical team with nurse involvement. Key decisions include:

• NIV vs. invasive mechanical ventilation: Most patients choose NIV and decline tracheostomy. The minority who choose tracheostomy must understand they will require ventilator support indefinitely. Document this decision clearly.
• Artificial nutrition: PEG tube decisions should be made before swallowing failure, not during crisis.
• Resuscitation status: DNRO/DNR discussions should be explicit, documented, and revisited as disease progresses.
• Hospice eligibility: ALSFRS-R ≤25 combined with FVC <30%, or patient’s refusal of ventilatory support with FVC below 30%, is a standard eligibility threshold. Hospice can be introduced alongside disease-modifying treatment — they are not mutually exclusive.

Palliative symptom management in terminal ALS

In the terminal phase (typically dyspnea at rest, inability to communicate, total dependence in all ADLs), comfort-focused nursing care includes:

• Opioids for dyspnea and pain (morphine is evidence-based for dyspnea relief — it reduces the sensation of breathlessness without always causing respiratory depression at appropriate doses)
• Benzodiazepines for anxiety and air hunger
• Anticholinergics (glycopyrrolate, hyoscine) to reduce secretion pooling and the death rattle
• Mouth care and pressure injury prevention
• Family presence and emotional support

Voluntarily stopping eating and drinking (VSED)

VSED is a patient’s autonomous decision to stop all oral intake as a means of hastening death. It is legally and ethically recognized in all U.S. states as an exercise of patient autonomy. The nurse’s role is to support the patient’s informed decision-making (not direct, approve, or discourage), provide symptom management (oral care, comfort measures), and support the family. Nurses who have conscientious objections should inform their supervisor so alternative nursing assignment can be arranged.

NCLEX tips

1. UMN vs LMN: the classic trap NCLEX questions love testing whether you can sort signs correctly. UMN signs: spasticity, hyperreflexia, Babinski. LMN signs: fasciculations, flaccidity, atrophy, areflexia. ALS has both simultaneously — that’s the diagnostic clue.

2. Riluzole requires LFT monitoring Riluzole is hepatotoxic. LFTs at baseline → monthly for 3 months → quarterly. If AST/ALT exceeds 5× ULN, discontinue. The mechanism: glutamate excitotoxicity inhibition. Know both.

3. NIV threshold is FVC <50%, not hypoxia A common NCLEX distractor is waiting for SpO₂ to drop before initiating BiPAP. Wrong. Initiate NIV discussion when FVC is <50% predicted, or when orthopnea is present. Hypoxia is a late sign.

4. PEG before FVC drops below 50% PEG placement under sedation when FVC is already low risks respiratory failure. Time it while FVC is still >50%. The question may frame it as “when is the right time” — earlier is safer.

5. ALS does not cause sensory loss If a question describes ALS with numbness or paresthesia, that’s a red flag. Sensory tracts are spared. This differentiates ALS from multiple sclerosis and spinal cord injury. If sensory symptoms are present, reconsider the diagnosis.

6. Pseudobulbar affect vs depression Pseudobulbar affect: involuntary crying or laughing, disproportionate to emotional state, brief episodes. Depression: sustained low mood, anhedonia, hopelessness. Different presentations, different treatments — Nuedexta for pseudobulbar affect, antidepressants for depression.

7. ALSFRS-R scores: know the ranges Maximum score = 48 (normal). A score of 25 or below combined with FVC <30% = typical hospice threshold. Rate of decline (points per month) is more prognostically meaningful than a single score.

8. Bulbar-onset: aspiration is the priority When a question describes bulbar-onset ALS (speech slurring, swallowing difficulty, drooling), the priority intervention is aspiration precautions — upright positioning, diet modification, SLP referral — before any other intervention. Aspiration pneumonia is the most immediate risk.

9. Sialorrhea: glycopyrrolate is first-line Drooling in ALS is caused by impaired swallowing, not excess saliva production. First-line treatment is glycopyrrolate (anticholinergic). It does not cross the blood-brain barrier, minimizing CNS side effects compared to other anticholinergics.

10. Cognitive changes: ALS-FTD overlap Up to 15% of ALS patients develop frontotemporal dementia. Do not assume preserved cognition. This matters for informed consent, communication strategies, and caregiver education. A question that describes ALS with behavioral changes (disinhibition, apathy, executive dysfunction) is testing ALS-FTD awareness.

11. AMX0035 (Relyvrio) was withdrawn in 2024 – edaravone remains approved If an NCLEX-style question lists currently approved ALS medications, AMX0035 (Relyvrio) is no longer on the US market. It was FDA-approved in September 2022 on Phase 2 data, but the manufacturer withdrew it in April 2024 after the Phase 3 PHOENIX trial showed no benefit over placebo. Riluzole, edaravone, and tofersen (for SOD1-ALS only) are the currently approved disease-modifying options.

Related nursing references

This article is part of the neurological conditions cluster. For related topics:

• Parkinson’s disease nursing reference — dopaminergic degeneration, TRAP mnemonic, levodopa nursing considerations, Hoehn & Yahr staging
• Multiple sclerosis nursing reference — demyelination, McDonald criteria, disease-modifying therapies, UMN signs in MS vs ALS
• Spinal cord injury nursing — UMN vs LMN anatomy at spinal level, autonomic dysreflexia, SCI levels
• Glasgow Coma Scale reference — neurological status assessment, GCS scoring, NCLEX tips
• Head-to-toe assessment guide — systematic neurological assessment framework applicable across all conditions
• Drug classifications nursing reference — pharmacology classification system for NCLEX preparation
• Stroke nursing reference — UMN signs post-stroke, aspiration precautions, dysphagia management overlap with ALS